{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:50:03Z","timestamp":1774659003660,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":268,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"crossref","award":["10.13039\/501100004948"],"award-info":[{"award-number":["10.13039\/501100004948"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Inc."},{"name":"Astellas","award":["10.13039\/100004324"],"award-info":[{"award-number":["10.13039\/100004324"]}]},{"name":"Bristol-Myers Squibb","award":["10.13039\/100002491"],"award-info":[{"award-number":["10.13039\/100002491"]}]},{"name":"Eli Lilly"},{"name":"AstraZeneca","award":["10.13039\/100004325"],"award-info":[{"award-number":["10.13039\/100004325"]}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","award":["10.13039\/100004336"],"award-info":[{"award-number":["10.13039\/100004336"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gritstone Oncology"},{"name":"Astellas","award":["10.13039\/100004324"],"award-info":[{"award-number":["10.13039\/100004324"]}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"crossref","award":["10.13039\/100004328"],"award-info":[{"award-number":["10.13039\/100004328"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Xcovery"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"crossref","award":["10.13039\/100004334"],"award-info":[{"award-number":["10.13039\/100004334"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1093\/annonc\/mdz128","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T19:11:39Z","timestamp":1556737899000},"page":"1127-1133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB\/IV non-small-cell lung cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"R.J.","family":"Kelly","sequence":"first","affiliation":[]},{"given":"F.A.","family":"Shepherd","sequence":"additional","affiliation":[]},{"given":"A.","family":"Krivoshik","sequence":"additional","affiliation":[]},{"given":"F.","family":"Jie","sequence":"additional","affiliation":[]},{"given":"L.","family":"Horn","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"31","key":"10.1093\/annonc\/mdz128_bb0010","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1200\/JCO.2005.02.7078","article-title":"Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL\/INTACT gefitinib trials","volume":"23","author":"Bell","year":"2005","journal-title":"JCO"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdz128_bb0015","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/modpathol.3801018","article-title":"Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond","volume":"21","author":"Ladanyi","year":"2008","journal-title":"Mod Pathol"},{"issue":"13","key":"10.1093\/annonc\/mdz128_bb0020","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1093\/annonc\/mdz128_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/138920210793175903","article-title":"Lung cancer: are we up to the challenge?","volume":"11","author":"Esposito","year":"2010","journal-title":"Curr Genomics"},{"issue":"8","key":"10.1093\/annonc\/mdz128_bb0030","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2012.43.3912","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease","volume":"31","author":"Ohashi","year":"2013","journal-title":"JCO"},{"issue":"2","key":"10.1093\/annonc\/mdz128_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1093\/annonc\/mdz128_bb0040","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1111\/cas.13724","article-title":"Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations","volume":"109","author":"Murakami","year":"2018","journal-title":"Cancer Sci"},{"issue":"8","key":"10.1093\/annonc\/mdz128_bb0045","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/cas.13651","article-title":"ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naive Japanese patients with EGFR mutation-positive non-small-cell lung cancer","volume":"109","author":"Azuma","year":"2018","journal-title":"Cancer Sci"},{"issue":"24","key":"10.1093\/annonc\/mdz128_bb0050","doi-asserted-by":"crossref","first-page":"7467","DOI":"10.1158\/1078-0432.CCR-17-1447","article-title":"A phase I, dose escalation study of oral ASP8273 in patients with non-small cell lung cancers with epidermal growth factor receptor mutations","volume":"23","author":"Yu","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1093\/annonc\/mdz128_bb0055","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40265-015-0434-6","article-title":"Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK","volume":"75","author":"Califano","year":"2015","journal-title":"Drugs"},{"key":"10.1093\/annonc\/mdz128_bb0060","doi-asserted-by":"crossref","first-page":"98771","DOI":"10.18632\/oncotarget.21936","article-title":"Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model","volume":"8","author":"Tan","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1093\/annonc\/mdz128_bb0065","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1093\/annonc\/mdz128_bb0070","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1093\/annonc\/mdz128_bb0075","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1634\/theoncologist.2014-0089","article-title":"U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations","volume":"19","author":"Khozin","year":"2014","journal-title":"Oncologist"},{"issue":"1","key":"10.1093\/annonc\/mdz128_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdz128_bb0085","unstructured":"Iressa (Gefitinib) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP 2018."},{"key":"10.1093\/annonc\/mdz128_bb0090","unstructured":"Terceva (Erlotinib) [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc. 2016."}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419312359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz128\/28937538\/mdz128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/7\/1127\/29209951\/mdz128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:06:28Z","timestamp":1668711988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419312359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0923753419312359"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz128","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB\/IV non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdz128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 THE AUTHORS. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}